62
Participants
Start Date
August 1, 2011
Primary Completion Date
February 1, 2012
Study Completion Date
February 1, 2012
LAS100977 0.313 μg
Dry powder inhalation, once-daily, single-dose
LAS100977 0.625 μg
Dry powder inhalation, once-daily, single-dose
LAS100977 1.25 μg
Dry powder inhalation, once-daily, single-dose
LAS100977 2.5 μg
Dry powder inhalation, once-daily, single-dose
Salbutamol 400 μg
Pressurized inhalation suspension, once-daily, single-dose
Salbutamol placebo
Pressurized inhalation, once-daily
LAS100977 placebo
Dry powder inhalation, once-daily
Almirall Investigational Sites#6, Berlin
Almirall Investigational Sites#4, Berlin
Almirall Investigational Sites#1, Berlin
Almirall Investigational Sites#8, Hamburg
Almirall Investigational Sites#2, Großhansdorf
Almirall Investigational Sites#3, Frankfurt
Almirall Investigational Sites#5, Wiesbaden
Almirall Investigational Sites#2, London
Almirall Investigational Sites#1, Manchester
Lead Sponsor
AstraZeneca
INDUSTRY